New Canadian Insights on Switching to Longer-Acting Therapy for Hemophilia A – WFH
World Federation of hemphilia (WFH) shared on X about a recent article by Davide Matino et al, published in Haemophilia Journal:
”A new Canadian study explores outcomes for people with hemophilia A (12+) who switched to a longer-acting treatment, looking at bleeding, quality of life, infusion frequency, and treatment satisfaction.”
Title: Canadian Clinical Experience on Switching From Standard Half-life Recombinant Factor VIII (rFVIII), Octocog Alfa, to Extended Half-life rFVIII, Damoctocog Alfa Pegol, in Persons With Haemophilia A ≥ 12 Years Followed in a Comprehensive Haemophilia Care Program in Canada
Authors: Davide Matino, Anthony K. C. Chan, Kay Decker, Emma Iserman, Andrea N. Edginton, Olayide Oladoyinbo, Elisabetta Trinari, Arun Keepanasseril, Alfonso Iorio
Read the Full Article on Haemophilia Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 24, 2026, 06:42Deepthi Krishna: World Blood Donor Day 2026 Celebrations at Rela Hospital
-
Jun 24, 2026, 03:36Ana Pedrero Gil: A New Approach to Post-Tonsillectomy Hemorrhage
-
Jun 24, 2026, 02:59Melissa Hollo: Making Early Anemia Detection the Standard of Care
-
Jun 24, 2026, 02:51Bruno Pougault: The Thin Line Between Bleeding and Clotting
-
Jun 23, 2026, 23:30Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis